Maegim한국어

JW생명과학

234080KOSPISector: Pharma & Biotech
₩11,030▼ 0.45%Market cap ₩174.7BAs of Jul 21, 2026 close · updated once daily
A
Grade A70 ptsTop 12% of 2,523 stocks
Financial strength
64.7
Growth momentum
59.6
Price attractiveness
83.6

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

64.7
How much debt does it carry relative to equity?
Debt-to-equity ratio
44.3%
✓ Above median · Top 42.9% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
104.6%
✗ Below median · Top 75.8% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
12.9%
✓ Above median · Top 14.2% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
13.0%
✓ Above median · Top 8.3% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

59.6
How much did revenue grow in a year?
Revenue growth (YoY)
15.9%
✓ Above median · Top 27.6% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
10.9%
✓ Above median · Top 31% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-7.3%
✗ Below median · Top 60.9% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
22.7%
✓ Above median · Top 42.2% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

83.6
Is the price expensive relative to earnings?
P/E (price-to-earnings)
6.1x
✓ Above median · Top 5.5% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.79x
✓ Above median · Top 27.4% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15